Trial Profile

A phase III study of OT-101 in high-grade gliomas

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 14 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trabedersen (Primary)
Indications Glioma
Focus Registrational; Therapeutic Use
Sponsors Mateon Therapeutics; Oncotelic Therapeutics

Most Recent Events

11 Jun 2024 According to an Oncotelic Therapeutics media release, the company announced today its CEO- Dr. Vuong Trieu will speak at the 20th Annual Congress of International Drug Discovery Science & Technology (IDDST) (Europe), June 17-19, 2024 at Budapest, Hungary regarding this trial .
28 Dec 2022 According to an Oncotelic Therapeutics media release, the company is working with multiple regulatory agencies, including the United States Food and Drug Administration to initiate the trial.
30 Apr 2019 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com